Arrowstreet Capital, Limited Partnership Nurix Therapeutics, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $114 Billion
- Q2 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 60,084 shares of NRIX stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,084
Previous 187,743
68.0%
Holding current value
$1.63 Million
Previous $2.76 Million
54.57%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
188Shares Held
67.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$185 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$120 Million6.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$109 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$105 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$105 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.28B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...